Multifocal Electroretinogram Findings after Intravitreal Bevacizumab Injection in Choroidal Neovascularization of Age-Related Macular Degeneration
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the changes in multifocal electroretinogram (mfERG) and optical coherence tomography (OCT) after intravitreal bevacizumab injection in the treatment of age-related macular degeneration (AMD). Methods: Twenty-one eyes with choroidal neovascularization secondary to AMD were studied before and after intravitreal bevacizumab injection for best corrected visual acuity (BCVA), OCT, and mfERG. Results: The BCVA improved, while central macular thickness and total macular volume in OCT decreased after intravitreal bevacizumab injection (p = 0.03, 0.01, and 0.01, respectively). In mfERG, the amplitude of P1, and implicit time of P1 and N1 indicated a statistically significant improvement of retinal response after intravitreal bevacizumab injection. Conclusions: There is a potential role for mfERG in evaluating the effect on retinal function of intravitreal bevacizumab injection.
Abstract
Purpose: To evaluate the changes in multifocal electroretinogram (mfERG) and optical coherence tomography (OCT) after intravitreal bevacizumab injection in the treatment of age-related macular degeneration (AMD). Methods: Twenty-one eyes with choroidal neovascularization secondary to AMD were studied before and after intravitreal bevacizumab injection for best corrected visual acuity (BCVA), OCT, and mfERG. Results: The BCVA improved, while central macular thickness and total macular volume in OCT decreased after intravitreal bevacizumab injection (p = 0.03, 0.01, and 0.01, respectively). In mfERG, the amplitude of P1, and implicit time of P1 and N1 indicated a statistically significant improvement of retinal response after intravitreal bevacizumab injection. Conclusions: There is a potential role for mfERG in evaluating the effect on retinal function of intravitreal bevacizumab injection.
참고문헌 (28)
- Friedman DS, "Prevalence of age-related macular degeneration in the United States", Arch Ophthalmol, 122, pp.564~572 (2004)
- Kroll P, "Which treatment is best for which AMD patient?", Br J Ophthalmol, 90, pp.128~130 (2006)
- Adamis AP, "The role of vascular endothelial growth factor in ocular health and disease", Retina, 25, pp.111~118 (2005)
- Ferrara N, "Vascular endothelial growth factor:basic science and clinical progress", Endocr Rev, 25, pp.581~611 (2004)
- Cohen SY, "Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia", Retina, 29, pp.1062~1066 (2009)
- Modarres M, "Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab(Avastin)for treatment of CNV associated with AMD", Retina, 29, pp.319~24 (2009)
- Tatar O, "Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization", Arch Ophthalmol, 126, pp.782~790 (2008)
- Schouten JS, "A systematic review on the effect of bevacizumab in exudative age-related macular degeneration", Graefes Arch Clin Exp Ophthalmol, 247, pp.1~11 (2009)
- Avery RL, "Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration", Ophthalmology, 113, pp.363~372.e5 (2006)
- Rich RM, "Short-term safety and efficacy of intravitreal bevacizumab(Avastin)for neovascular age-related macular degeneration", Retina, 26, pp.495~511 (2006)
- 김용환, "나이관련황반변성에 의한 맥락막혈관신생에서 유리체내 베바시주맙 주입술의 장기효과", 대한안과학회지, 49(12), pp.1935~1940 (2008), 대한안과학회
- Karanjia R, "Electrophysiological effects of intravitreal Avastin(bevacizumab)in the treatment of exudative age-related macular degeneration", Br J Ophthalmol, 92, pp.1248~1252 (2008)
- Moschos MM, "Intravitreal use of bevacizumab(Avastin)for choroidal neovascularization due to ARMD:a preliminary multifocal-ERG and OCT study.Multifocal-ERG after use of bevacizumab in ARMD", Doc Ophthalmol, 114, pp.37~44 (2007)
- Maturi RK, "Electrophysiologic findings after intravitreal bevacizumab(Avastin)treatment", Retina, 26, pp.270~274 (2006)
- Berrow EJ, "The electroretinogram:a useful tool for evaluating age-related macular disease?", Doc Ophthalmol, 121, pp.51~62 (2010)
- 오세범, "나이관련 황반변성의 맥락막신생혈관에서 베바시주맙 유리체강내 주입술 효과와 예후인자", 대한안과학회지, 50(2), pp.202~210 (2009), 대한안과학회
- Maturi RK, "Multifocal electroretinography and its clinical application. In Retina and optic nerve imaging", pp.213~230 (2003), Lippincott Williams & Wilkins
- Hood DC, "Retinal origins of the primate multifocal ERG:implications for the human response", Invest Ophthalmol Vis Sci, 43, pp.1673~1685 (2002)
- Hood DC, "Assessing retinal function with the multifocal technique", Prog Retin Eye Res, 19, pp.607~646 (2000)
- Marmor MF, "Topography of cone electrophysiology in the enhanced S cone syndrome", Invest Ophthalmol Vis Sci, 40, pp.1866~1873 (1999)
- Kretschmann U, "Familial macular cone dystrophy:diagnostic value of multifocal ERG and two-color threshold perimetry", Graefes Arch Clin Exp Ophthalmol, 237, pp.429~432 (1999)
- Li J, "Reduced amplitude and delayed latency in foveal response of multifocal electroretinogram in early age related macular degeneration", Br J Ophthalmol, 85, pp.287~290 (2001)
- Kondo M, "Clinical evaluation of multifocal electroretinogram", Invest Ophthalmol Vis Sci, 36, pp.2146~2150 (1995)
- Schneck ME, "Comparison of mfERG waveform components and implicit time measurement techniques for detecting functional change in early diabetic eye disease", Doc Ophthalmol, 108, pp.223~230 (2004)
- Hood DC, "Assessment of local retinal function in patients with retinitis pigmentosa using the multi-focal ERG technique", Vision Res, 38, pp.163~179 (1998)
- Seeliger M, "Multifocal electroretinography in retinitis pigmentosa", Am J Ophthalmol, 125, pp.214~226 (1998)
- Miyake Y, "Occult macular dystrophy", Am J Ophthalmol, 122, pp.644~653 (1996)
- Hood DC, "The multifocal electroretinogram", J Neuroophthalmol, 23, pp.225~235 (2003)